empasiprubart Updated Aug 22
Watch for Phase 3 topline MMN data (estimated primary completion Sep 2026). Positive data could add a new pipeline pillar, but empasiprubart is not the primary value driver at argenx, Vyvgart's commercial trajectory and the myositis readout for efgartigimod are larger stock-moving events. A Phase 2 dermatomyositis readout is also expected by November 2026.
- Empasiprubart targets large, underserved autoimmune markets (MMN has no approved drug; dermatomyositis has limited options) where a successful IVIg alternative could carve a significant niche.
- The Phase 3 MMN head-to-head vs IVIg is a high bar, but a win would rapidly establish empasiprubart as a standard-of-care challenger in a $1B+ addressable market.
- argenx has a strong commercial infrastructure and deep immunology expertise from Vyvgart, enabling a swift launch if data support approval.
- Empasiprubart is a small piece of the argenx story, Vyvgart generates ~$1.5B/quarter. Even a successful Phase 3 readout would be a modest driver for a ~$1,040 stock with 23 analysts already rating it Buy.
- The Phase 3 MMN trial is a head-to-head versus established IVIg therapy. Competitive efficacy and safety data are required to win share, a high bar for a novel complement inhibitor.
- The Phase 2 dermatomyositis study enrolled only 3 patients, far too small for any efficacy signal, making it very early-stage and high-risk.